AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04882878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.
Study NCT04882878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
Study NCT04882878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care treatment
Description: Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
Study NCT05181618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Study NCT05668325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini trampoline exercise group
Description: In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
Study NCT05668325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: In this study, patients were visited at home once a week for eight weeks and their feet were checked.
Study NCT06369233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MegaShield®-SP
Description: MegaShield®-SP application Lumbar discectomy or laminectomy
Study NCT06369233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix-SP Plus
Description: Guardix-SP Plus application Lumbar discectomy or laminectomy
Study NCT05296538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broad-Minded Affective Coping Intervention
Description: The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
Study NCT05296538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Assessment and Signposting
Description: A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
Study NCT05296538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Risk Assessment and Signposting
Description: A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
Study NCT04517110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Description: Pregabalin 300 mg, capsule
Study NCT04517110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Description: Pregabalin 75 mg twice daily, capsules
Study NCT04517110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin 300 mg Placebo
Description: Placebo, matching Pregabalin 300 mg capsule
Study NCT04517110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin 75 mg Placebo
Description: Placebo, matching Pregabalin 75 mg capsules
Study NCT04517110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT04517110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care
Study NCT04955301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
Study NCT06087731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (8mg/kg) every 4 wekks
Study NCT06543940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: vancomycin dose is 7.5 to 10 mg/kg
Study NCT05164263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
Study NCT05157958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-SHEET
Description: Weekly administration
Study NCT05157958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Control
Description: Weekly administration
Study NCT05832567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
Study NCT05832567 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
Study NCT05832567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Open Placebo
Description: The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
Study NCT06227013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whistleblowing intervention
Description: the participated nurses will receive session about Whistleblowing
Study NCT05508464 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: SABR
Description: SABR to all tumors 6 Gy x 5 over three weeks
Study NCT05508464 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Standard of Care
Description: Standard of care palliative radiotherapy
Study NCT06072365 — intervention group
Intervention type: OTHER
Intervention: nutritional intake questionnaire
Description: patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
Study NCT05588908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (phase II)
Description: Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
Study NCT04300140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is experimental drug
Study NCT04300140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (Cabo)
Description: Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
Study NCT04300140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is standard of care in the first line treatment of ccRCC
Study NCT04731337 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the tip of the upper and lower canine teeth.
Study NCT04731337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the tip of the upper and lower canine teeth.
Study NCT06024889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
Study NCT04783714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Nutra+ Cholesterol Balance
Description: Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
Study NCT04783714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
Study NCT04976322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol
Description: Subjects will receive dapirolizumab pegol at prespecified time-points.
Study NCT04956432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640 Dose 1 ,tablets, QD
Study NCT04956432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300mg, tablets, QD
Study NCT04016818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
Study NCT04016818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast-dedicated PET camera
Description: Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
Study NCT05046301 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT05046301 — intervention group
Intervention type: OTHER
Intervention: Contrast Agent
Description: Given IV
Study NCT05046301 — intervention group
Intervention type: PROCEDURE
Intervention: Contrast-Enhanced Mammography
Description: Undergo contrast-enhanced mammography
Study NCT05046301 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04499781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS II mHealth Intervention
Description: Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
Study NCT04499781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACCESS II control condition
Description: Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
Study NCT06228625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Group
Description: * Wand Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep.)~* Codmann Exercises (In each direction with front-back, right-left, clockwise and counterclockwise movements \*10 rep.)~* Finger Ladder (flexion and abduction directions \* 10 rep.)~* Strengthening Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep).~* Posterior, anterior and inferior capsule stretching ,pectoral muscle stretching \* 10 rep.
Study NCT06228625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Awareness Training Group
Description: * Supine: Body scan, contraction-relaxation exercises, strength recovery exercises combined with sound, stretching exercises, cross and star stretching.~* Sitting: Teaching the correct body alignment while sitting, exercise to restore the correct body alignment,~* Standing: Weight bearing exercises within stability limits, midline descent and elevation exercises, midline rotation exercises, wave motion, pushing movement combined with oblique weight bearing.
Study NCT06228625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitative Game Exercise Group
Description: * Cone Knockout: The game requires touching the cones that appear alternately on the right and left within one minute.~* Space Pong: It is required to play by hitting the ball with the right or left hand. It requires only upper extremity use and has seven abductions. Scoring is based on the ball hit.~* Reaction: It is a game that requires touching the green dots that appear on the screen within a certain period. The points received vary depending on the speed of touching the dots. Points are lost when the red dots are touched.~* Whack A Male: The player has 3 rights, and it requires using the upper extremity to hit the moles that come out of 5 holes at different times. A mole with a thorn on its head and a bomb should not be hit. Before the spiny mole emerges, a red light appears in the hole where it will emerge.
Study NCT04908865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.
Study NCT05075122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
Study NCT05075122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim for Injection
Description: 75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
Study NCT04908865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy will be continued.
Study NCT06557876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation by pulse field ablation
Description: Pulse Field Ablation (PFA) is a non-thermal energy based on high voltage, ultra-short energy pulses applied selectively to cardiomyocytes.
Study NCT06557876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation by cryoablation
Description: Cryoablation is a conventional thermal energy, also delivered with a single-shot cryoballoon device.
Study NCT06637800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
Description: The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
Study NCT06639828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
Study NCT05410509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-arterial embolization (TAE)
Description: Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
Study NCT05075122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab injection
Description: 200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
Study NCT05075122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: 200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
Study NCT05996471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH3810109
Description: VH3810109 will be administered.
Study NCT05996471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir
Description: Cabotegravir will be administered.
Study NCT05969145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application of thermophor
Description: The experimental group will be given hot and cold application to the bladder
Study NCT05996471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Pre-baseline SOC antiretroviral therapy (ART) will be administered.
Study NCT05996471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered.
Study NCT05989841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Guide
Description: Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
Study NCT05989841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Control
Description: Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention.
Study NCT04634513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: strain CVD 1208S-122
Description: Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
Study NCT04634513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate buffer
Study NCT06506279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorTec Brain Interchange (BIC) System
Description: Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
Study NCT05156398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: Rimegepant 75mg or 50mg (2 X 25mg) ODT
Study NCT05156398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 75mg or 50mg (2 X 25mg) ODT
Study NCT04743141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant (PF-07899801)
Description: Rimegepant 75 mg, 50 mg or 35 mg ODT
Study NCT05367713 — intervention group
Intervention type: OTHER
Intervention: patients having had an osteitis of the cranial flap after craniectomy
Description: description of management and failure of cranial flap after craniectomy
Study NCT05152368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05392166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound
Description: blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.